RAUWILOID Drug Patent Profile
✉ Email this page to a colleague
When do Rauwiloid patents expire, and when can generic versions of Rauwiloid launch?
Rauwiloid is a drug marketed by 3M and is included in one NDA.
The generic ingredient in RAUWILOID is alseroxylon. Additional details are available on the alseroxylon profile page.
Summary for RAUWILOID
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 17 |
Patent Applications: | 4,317 |
Formulation / Manufacturing: | see details |
DailyMed Link: | RAUWILOID at DailyMed |
US Patents and Regulatory Information for RAUWILOID
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3m | RAUWILOID | alseroxylon | TABLET;ORAL | 008867-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |